Cspc Pharmaceutical Group Limited Announces That the Peramivir Injection (15Ml:0.15G) (The "Product") Developed by the Group Has Obtained Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China, and Is Deemed to Have Passed the Consistency Evaluation of Quality and Efficacy for Generic Drugs

The board of directors of CSPC Pharmaceutical Group Limited announced that the Peramivir Injection (15ml:0.15g) (the "Product") developed by the Group has obtained drug registration approval granted by the National Medical Products Administration of the People's Republic of China, and is deemed to have passed the consistency evaluation of quality and efficacy for generic drugs. Peramivir is a cyclopentane anti-viral drug against influenza virus. It effectively inhibits both human influenza A and B viruses by binding to the active site of the influenza virus neuraminidase.

The Product can be used for the treatment of influenza A or B. The approval of the Product will further enrich the Group's anti-infective product portfolio.